L. Wong

发表

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

G. Kaplan, R. Chen, L. Corral, 1999, Bioorganic & medicinal chemistry letters.

Inhibitors of TNF-Thalidomide Analogues That Are Potent Activation by Two Distinct Classes of Differential Cytokine Modulation and T Cell

P. Haslett, G. Kaplan, L. Corral, 1999 .

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

P. Schafer, K. Blease, J. Leisten, 2009, Journal of medicinal chemistry.

Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.

T. Harvey, R. Syed, C. Dominguez, 2005, Bioorganic & medicinal chemistry letters.

Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.

Matthew R. Lee, A. Tasker, Bin Wu, 2010, Journal of medicinal chemistry.

Identification of triazolopyridazinones as potent p38α inhibitors.

S. Chmait, B. Herberich, Matthew R. Lee, 2012, Bioorganic & medicinal chemistry letters.

Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.

S. Chmait, K. Miner, Matthew R. Lee, 2010, Bioorganic & medicinal chemistry letters.

Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.

Christopher Mohr, Lisa Sherman, S. Chmait, 2010, Journal of medicinal chemistry.

Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production

Gilla Kaplan, G. Kaplan, L. Corral, 1999 .

Thalidomide analogs and PDE4 inhibition.

L. Corral, D. Stirling, G. Muller, 1998, Bioorganic & medicinal chemistry letters.

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

P. Haslett, G. Kaplan, R. Chen, 1999, Journal of immunology.

Signal Transduction and Ligand Specificity of the Human Monocyte Chemoattractant Protein-1 Receptor in Transfected Embryonic Kidney Cells (*)

S. J. Myers, I. Charo, L. Wong, 1995, The Journal of Biological Chemistry.

Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.

R. Syed, B. Herberich, Matthew R. Lee, 2008, Journal of medicinal chemistry.

3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.

R. Syed, Matthew R. Lee, A. Tasker, 2008, Journal of medicinal chemistry.

Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.

S. Chmait, K. Miner, Matthew R. Lee, 2009, Bioorganic & medicinal chemistry letters.

Monocyte chemoattractant protein-3, but not monocyte chemoattractant protein-2, is a functional ligand of the human monocyte chemoattractant protein-1 receptor.

P. Proost, J. Van Damme, I. Charo, 1995, Journal of immunology.

Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.

S. Chmait, B. Herberich, Matthew R. Lee, 2010, Journal of medicinal chemistry.